An observational study in Humeral Fractures, Proximal and Humeral Fractures, sponsored by Zimmer Biomet. Active, not recruiting at 5 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Zimmer Biomet · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Shoulder Fractures by Zimmer Biomet — 7 open to participants now, 9 under way, none of them phase 3. Shoulder Fractures · Zimmer Biomet.
Among the 12 studies in Shoulder Fractures by Zimmer Biomet, this one is the 3rd largest by planned enrollment of the 10 observational ones that give a count, is one of 3 that started in 2022, is one of 10 observational ones, and was the 5th registered.
113 studies on the registry are indexed under Shoulder Fractures; 30 are open to participants now.
Browse Shoulder Fractures studies →7 of the 12 studies in Shoulder Fractures by Zimmer Biomet are open now, in 7 countries. Recruiting first, the newest first:
Zimmer Biomet · Sites in Germany, Netherlands
Ages 20+
Zimmer Biomet · Sites in Spain
Ages 18+
Zimmer Biomet · Sites in United States, Japan, New Zealand
Ages 20+
Zimmer Biomet · Sites in United States
Ages 20+
Zimmer Biomet · Sites in United States, Denmark
Ages 18–100
By country, each count listing its studies:
Of the 18 Shoulder Fractures studies recruiting now, 13 (72%) set no upper age limit and 3 (17%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2022.
This study's planned enrollment of 100 is close to the median of 97 across 60 observational studies indexed under Shoulder Fractures.
Median enrollment 360 across the 2 interventional studies, 69 across the 10 observational. Of the 3 that completed or were terminated, 2 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
Zimmer Biomet is the lead sponsor of 275 studies on the registry; 28 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 19 (86%) have results posted.
2 of the studies in Shoulder Fractures by Zimmer Biomet that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03626038Zimmer BiometPost Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System | 2026-12 |
| NCT05019664Zimmer BiometAffixus Natural Nail System Humeral Nail PMCF | 2027-08 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Shoulder Fractures by Zimmer Biomet, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A commercially available product clinical study which aims to confirm the safety, performance and clinical benefits to the patient of the Affixus Natural Nail upper arm (humerus) bone nail system for both the implant itself and the instrumentation used during surgery.
Study objective:
The objectives of this observational, prospective study with optional retrospective enrollment are to confirm safety, performance and clinical benefits of the Affixus Natural Nail System Humeral Nail and its instrumentation by analyzing adverse event records, fracture/osteotomy healing and functional outcome and adverse events.
The safety of the system will be assessed by monitoring the frequency and incidence of adverse events. Relation of the events to implant, instrumentation and/or procedure should be specified.
The performance and clinical benefits will be evaluated by assessment of fracture/osteotomy healing and functional outcome of all enrolled study subjects.
Study Endpoints:
Primary endpoint:
The primary endpoint is bone union after 12 months since surgery.
Secondary endpoint:
The secondary endpoints will be evaluating functional outcomes (Range of Motion, \& American Shoulder and Elbow Surgeons questionnaire), quality of life questionnaire (EQ-5D-5L), radiographic findings and adverse events including re-operation of all enrolled study subjects at the defined follow up time points.
Consecutive series of 100 subjects globally implanted with the Affixus Natural Nail System Humeral Nail for temporary fixation and stabilization of fractures or osteotomies of the humerus.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patient with either a proximal humeral fracture or humeral shaft fracture requiring surgical intervention and be eligible for fixation by intramedullary nailing.
Bone Union
The primary endpoint is bone union after 12 months since surgery. (Bone union defined as no pain or tenderness at the site, and strong enough to allow normal activities.)
Time frame: 12 months
Range of Motion
The Range of Motion (total shoulder motion, active and passive) of the affected and contralateral (right and left) upper arm will be measured.
Time frame: 12 months
EQ-5D-5L
EQ-5D-5L Health Questionnaire is completed by the patient and assesses his/her general health status. The EQ-5D-5L is used to derive a quality of life index used for health economics considerations.
Time frame: 12 months
Radiographic Findings
Postoperative Radiographic Evaluation collects radiographic parameters like bridging callus, visible fracture line, device fracture, device loosening and union status (AP, lateral, and auxiliary view).
Time frame: 12 months
Adverse Events
Adverse Event Report is completed as needed for each complication which is noted.
Time frame: 12 months
Plan to share: Undecided — This aspect of the study is undecided.
No publications or documents are linked to this record.
Started Aug 2022 (actual). Primary completion is estimated for Aug 2027, 60 months after the start.
Of 30 observational studies under Shoulder Fractures, half reached primary completion within 83 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 109. This study's planned 60 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.